Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics, Inc. received a joint Schedule 13G filing showing that Dimension Capital I, L.P. and affiliated reporting persons collectively beneficially hold 4,757,563 shares of the issuer's common stock, representing 7.7% of the class. The filing lists the reporting persons as Dimension Management, L.P., Dimension Capital I GP, LLC, Dimension Management GP, LLC, Dimension Capital I, L.P. and individuals Adam Goulburn, Zavain Dar, and Nan Li. The cover information states the ownership percentages are calculated using 61,759,350 outstanding shares reported by the issuer as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the disclosed shares and certify the shares were not acquired to change control of the company.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 3,725,000 shares of Monte Rosa Therapeutics common stock, representing 6.1% of the class. The reporting persons state they have sole voting and sole dispositive power over these shares and that the shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
The percentage is calculated using 61,509,821 shares outstanding as of May 5, 2025, per the company's quarterly report. The filing includes a certification that the securities were acquired in the ordinary course of business and were not acquired to change or influence control; signatures appear for Avoro and for Behzad Aghazadeh.